Mineralocorticoid receptor antagonists for heart failure (Q37955919)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on 14 November 2011

Language	Label	Description	Also known as
English	Mineralocorticoid receptor antagonists for heart failure	scientific article published on 14 November 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Mineralocorticoid receptor antagonists for heart failure (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

0 references

1

object named as

Arthur Mark Richards

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

language of work or name

0 references

publication date

14 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Expert Opinion on Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

2801-2815

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Stimulation of active sodium transport by the isolated toad bladder with aldosterone in vitro

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Evidence for secretion of an aldosterone-stimulating hormone by the kidney

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

The role of the renin-angiotensin system in the control of aldosterone secretion

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Control of aldosterone secretion: a model for convergence in cellular signaling pathways

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Aldosterone and mineralocorticoid receptors in the cardiovascular system

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

High rate of detection of primary aldosteronism, including surgically treatable forms, after ???non-selective??? screening of hypertensive patients

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Distinguishing the antihypertensive and electrolyte effects of eplerenone

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Mineralocorticoid-induced increase in beta-adrenergic receptors of cultured rat arterial smooth muscle cells

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Pathophysiological effects of aldosterone in cardiovascular tissues

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Rapid actions of aldosterone in vascular health and disease--friend or foe?

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Rapid nongenomic effects of aldosterone on human forearm vasculature

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Aldosterone induces contraction of the resistance arteries in man.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Lack of rapid aldosterone effects on forearm resistance vasculature in health

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

From inflammation to fibrosis: a stiff stretch of highway

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Aldosterone and vascular inflammation

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

TGF-beta1 induces cardiac hypertrophic responses via PKC-dependent ATF-2 activation

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

CTGF expression is induced by TGF- beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Extra-adrenal glucocorticoids and mineralocorticoids: evidence for local synthesis, regulation, and function.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Aldosterone is produced from ventricles in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Aldosterone production is activated in failing ventricle in humans

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

The clinical implications of aldosterone escape in congestive heart failure.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Spironolactone improves lung diffusion in chronic heart failure.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Effects of Spironolactone and Metoprolol on QT Dispersion in Heart Failere

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Effects of canrenoate plus angiotensin-converting enzyme inhibitors versus angiotensin-converting enzyme inhibitors alone on systolic and diastolic function in patients with acute anterior myocardial infarction.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Spironolactone Reduced Arrhythmia and Maintained Magnesium Homeostasis in Patients With Congestive Heart Failure

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Stu

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect?

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Effect of aldosterone antagonism on exercise tolerance, Doppler diastolic function, and quality of life in older women with diastolic heart failure

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the [...]

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Use of aldosterone antagonists in heart failure

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Irbesartan in patients with heart failure and preserved ejection fraction

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure)

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.631524

21 January 2018

Identifiers

10.1517/14656566.2011.631524

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37955919&oldid=2088638653"